Clinical Trial Search

Primary: Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 15.3; 9.2 Months

Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 — 28.9; 12.0 percentage of participants — p=<0.0001

Primary: Recruitment Rate — 150; 150 Participants

Primary: Number of Patients With Histology-confirmed Lesions (Ta, T1, or CIS) Who Have at Least One Such Lesion Found by Hexvix Blue Light Cystoscopy But Not by White Light…

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and as Per Severity — 30; 56; 14; 37 Participants

Primary: Glasgow Outcome Scale (GOS) — 189; 183; 109; 114 Participants

Primary: Incidence of Adverse Sedation-Related Events in Musculoskeletal System During Sedation — 2.8; 3; 2.5500 score on a scale — p=0.016

Primary: Clinical Benefit Rate (CBR) of Tumour Response Assessed by Blinded Independent Central Review (BICR) at Week 24 — 62.79 percentage of participants

Primary: Primary Composite Outcome — 85; 89; 90; 86 Participants

Primary: Number of Pemphigus Vulgaris (PV) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy — 44; 20 Participants

Primary: 30 Minute Pain Score — 3; 3; 3 score on a scale

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded by Severity — 98; 89; 123; 91 Participants

Primary: Weight — 127; 130; 126; 75 kilograms

Primary: Percentage of Participants With Healing by Day 8 — 194 Participants

Primary: Time to Complete Eschar Removal (in Days) — 0.99; 5.99 Days — p=0.0008